- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 12 May 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 10 listed it in both
- Shares listed
- 163,078,289
- combined, among listed positions
- Reported value
- $6.3bn
- combined, at the quarter end
Among the 95 comparable managers: 7 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing GSK in Q1 2025
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Dodge & Coxexisting position · 78,651,833 shares now+10,210,921
- Fidelity (FMR LLC)existing position · 60,120,517 shares now+7,297,485
- Holocene Advisors LPexisting position · 5,305,042 shares now+4,792,922
- Acadian Asset Management LLCexisting position · 3,982,324 shares now+2,663,270
- T. Rowe Price Associates Incexisting position · 7,722,314 shares now+155,392
Reductions
- Schonfeld Strategic Advisors LLCexisting position · 806,507 shares now-1,430,527
- Bridgewater Associates LPexisting position · 1,203,095 shares now-1,044,596
- Renaissance Technologies LLCexisting position · 1,982,153 shares now-773,040
- Quantbot Technologies LPexisting position · 48,801 shares now-40,570
New positions and exits
New (0)
No new position among listed positions.
Exited (2)
- Voloridge Investment Management LLCwas $73m
- Woodline Partners LPwas $37m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2022 | 1 | $19m | n.a. | n.a. |
| Q3 2022 | 18 | $3.9bn | n.a. | n.a. |
| Q4 2022 | 18 | $4.9bn | n.a. | n.a. |
| Q1 2023 | 13 | $4.4bn | n.a. | n.a. |
| Q2 2023 | 13 | $4.3bn | n.a. | n.a. |
| Q3 2023 | 16 | $4.5bn | n.a. | n.a. |
| Q4 2023 | 13 | $4.5bn | 6 | 7 |
| Q1 2024 | 13 | $5.3bn | 5 | 7 |
| Q2 2024 | 10 | $4.6bn | 6 | 4 |
| Q3 2024 | 10 | $4.9bn | 6 | 3 |
| Q4 2024 | 13 | $4.9bn | 11 | 2 |
| Q1 2025 | 11 | $6.3bn | 7 | 6 |
| Q2 2025 | 10 | $6.2bn | 8 | 3 |
| Q3 2025 | 11 | $7.5bn | 6 | 5 |
| Q4 2025 | 11 | $8.8bn | 15 | 13 |
| Q1 2026 | 9 | $9.1bn | 9 | 19 |
| Q2 2026 | 11 | $7.5bn | 15 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GSK, latest filings →Back to the 13F Explorer →